Akari Therapeutics, Plc

Equities

AKTX

US00972G2075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.185 ^USD	-0.42%		+1.61%	-62.02%

Apr. 24	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT
Apr. 23	European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading	MT

Akari Therapeutics, Plc announced that it has received $2.000001 million in funding

December 28, 2023

On December 29, 2023, Akari Therapeutics, Plc closed the transaction. The company has now issued 947,868 unregistered American Depository Shares at a price of $2.11 per ADS for the gross proceeds of $2,000,001.48.

Latest news about Akari Therapeutics, Plc

European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 24	MT
European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading	Apr. 23	MT
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	Apr. 22	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 17	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	Apr. 16	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
ADRs End Lower, Leju Holdings Ltd. Declines 72%	Apr. 12	DJ
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	Apr. 12	MT
ADRs End Higher, Lixiang Education Holding Co. Ltd. Climbs 69%	Apr. 11	DJ
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	Apr. 11	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 10	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Apr. 09	MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	Apr. 08	MT
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower	Apr. 05	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	Apr. 03	MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	Apr. 02	MT
ADRs End Higher; Connect Biopharma Climbs 26%	Apr. 01	DJ
Akari Therapeutics, Plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday	Mar. 28	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	Mar. 25	MT
European Equities Traded in the US as American Depositary Receipts Ease Wednesday	Mar. 20	MT
European Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading	Mar. 19	MT
European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading	Mar. 18	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	Mar. 14	MT
Akari Therapeutics, Plc announced that it expects to receive $1.615 million in funding	Mar. 10	CI

Chart Akari Therapeutics, Plc

Duration

Period

More charts

Company Profile

Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Association for Research in Vision and Ophthalmology Meeting

More about the company

	1st Jan change	Capi.
AKARI THERAPEUTICS, PLC	-62.02%	9.39M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs